javascript:void(0) Background Few studies have investigated the relationship between baseline type 2 biomarker levels and clinical features in pediatric asthma, particularly in Th2-high phenotypes, which could provide insights into asthma prognosis and remission. Objective To explore the link between baseline type 2 biomarker levels and clinical manifestations in pediatric asthma, identifying predictors of clinical remission. Methods The study included 172 children with a mean age of 6.87±3.04 years, comprising 119 asthma patients and 53 non-respiratory symptom controls. Clinical evaluations such as lung function tests, FeNO, total IgE, blood eosinophil counts, and skin tests were conducted. Serum Th2 biomarkers were measured by ELISA. Patients were classified into Th2-high asthma based on eosinophil count and total IgE levels and further categorized into acute attack, persistent asthma, and clinical remission groups. Additionally, mouse models were used to measure TSLP levels in BALF, serum, and lung tissue by ELISA, mirroring the human study design. Result Serum TSLP levels were significantly higher in subjects with acute exacerbation and persistent asthma compared to those in remission and controls. A positive correlation was found between serum TSLP levels and clinical remission (OR=1.009; P<0.05). Mouse model data supported the clinical findings, showing increased TSLP levels in chronic stages. Conclusion Serum TSLP correlates with clinical remission in Th2-high asthma and, combined with lung function tests, may serve as a biomarker for asthma remission evaluation. Further studies with larger cohorts are warranted to validate these findings.